Loading data for ALZN — first visit, this takes a few seconds.
Alzamend Neuro Inc. (ALZN)
NasdaqCM: ALZN
· Real-Time Price · USD
1.63
+0.11 (7.24%)
At close: Aug 28, 2026, 3:59 PM
1.66
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Alzamend Neuro Inc. (ALZN) Stock Price, Analysis & Data
7.24% (1D)
| Bid | 1.2 |
| Market Cap | 8.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.77M |
| 0.19 | |
| -2.65 | |
| n/a | |
| -1.91 | |
| P/B (ttm) | 9.65 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2 |
| Volume | 373,319 |
| Avg. Volume (20D) | 147,219 |
| Open | 1.56 |
| Previous Close | 1.52 |
| Day's Range | 1.53 - 1.67 |
| 52-Week Range | 0.84 - 2.68 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ALZN
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric d...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 2021
Employees 4
Stock Exchange NasdaqCM
Ticker Symbol ALZN
Website https://www.alzamend.com
Financial Performance
In 2026, Alzamend Neuro's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -8.77M, an increase of 94.3%.
Financial StatementsEarnings Surprise
Alzamend Neuro has released their quarterly earnings on Jul 22, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.74 misses estimates by -0.07, with 92.19% YoY growth.
